Logo

PRENW

Prenetics Global Limited

PRENW

Prenetics Global Limited • NASDAQ
$0.03 ▼ -1.48% (-0.00)
Market Cap $349577
52w High $0.03
52w Low $0.02
Dividend Yield 0%
P/E 0
Volume 1
Outstanding Shares 13.24M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $23.555M ▲ $20.188M ▲ $-7.408M ▲ -31.45% ▲ $-0.53 ▲ $-6.724M ▲
Q2-2025 $17.68M ▲ $17.354M ▼ $-12.41M ▼ -70.192% ▼ $-0.94 ▼ $-10.889M ▲
Q1-2025 $17.312M ▲ $17.974M ▼ $-10.39M ▲ -60.016% ▲ $-0.8 ▲ $-11.004M ▲
Q4-2024 $10.488M ▲ $20.469M ▲ $-16.342M ▼ -155.812% ▼ $-1.29 ▼ $-24.89M ▼
Q3-2024 $7.778M $15.756M $-10.672M -137.211% $-0.84 $-10.931M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $23.726M ▼ $196.507M ▼ $35.305M ▼ $161.292M ▲
Q2-2025 $27.711M ▼ $199.106M ▼ $48.214M ▲ $150.982M ▼
Q1-2025 $58.528M ▼ $204.015M ▼ $42.899M ▲ $160.882M ▼
Q4-2024 $62.813M ▲ $213.575M ▼ $42.229M ▼ $170.389M ▼
Q3-2024 $42.832M $235.766M $55.67M $178.679M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-12.41M ▼ $0 $0 $0 $0 $0
Q1-2025 $-10.39M ▲ $0 $0 $0 $0 $0
Q4-2024 $-16.342M ▼ $0 $0 $0 $0 $0
Q3-2024 $-10.672M ▲ $0 $0 $0 $0 $0
Q2-2024 $-10.722M $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement Revenue has fallen sharply from its peak a few years ago and is now very small, suggesting the business is still searching for a scalable, repeatable growth engine after the COVID-era testing boom. Gross profit is positive, so the core services can be priced above direct costs, but overhead, marketing, and development spending remain much higher than gross profit. That leads to ongoing operating losses, negative EBITDA, and continued net losses each year. Earnings per share are deeply negative, reflecting both the small revenue base and the cost of building new businesses and technologies.

Balance Sheet

Balance Sheet The company keeps a relatively lean balance sheet with modest total assets and a meaningful but not large cash cushion. Cash has declined from prior highs, but the business still appears to have some financial flexibility. Debt levels are very low, so the company is not heavily burdened by interest obligations. Shareholders’ equity has improved from earlier negative levels to positive territory, although it has been gradually eroded by recurring losses. Overall, the balance sheet looks light on leverage but also constrained in size, which limits shock-absorbing capacity if results disappoint or investments take longer to pay off.

Cash Flow

Cash Flow Operating cash flow has been slightly negative in recent years, indicating the business still consumes cash rather than generating it, but the scale of the burn appears modest rather than extreme. Free cash flow follows the same pattern: small but persistent outflows, as limited capital spending and an asset-light model help keep investment needs relatively low. This means the main drain on cash is funding ongoing operations and growth initiatives, not heavy physical investment. Sustained improvement in operating cash flow will depend on scaling revenue faster than operating costs, or tightening spending if growth is slower than planned.

Competitive Edge

Competitive Edge Prenetics operates in a crowded and fast-moving space that includes genetic testing, early cancer detection, and consumer wellness. Its competitive edge comes from several angles: more comprehensive DNA testing for health rather than just ancestry; access to advanced liquid biopsy technology for early cancer screening; and a high-visibility wellness brand backed by a major celebrity. At the same time, the company faces intense competition from larger, better-funded diagnostics players and many smaller wellness brands. Success will hinge on turning its scientific advantages, strong branding, and partnerships into sustainable customer adoption and recurring revenue, especially in Asia where it is focused.

Innovation and R&D

Innovation and R&D Innovation is clearly at the center of the strategy. The company is advancing three key pillars: CircleDNA for comprehensive health-focused genetic insights; Insighta for cutting-edge, blood-based early cancer detection; and IM8 for science-backed, all-in-one supplements targeting longevity and wellness. The liquid biopsy work and the FRAGMA technology, in particular, represent high scientific ambition but also high execution and regulatory risk. The use of Bitcoin as a treasury asset and experiments with blockchain-based digital identity show a willingness to pursue unconventional ideas. Overall, Prenetics is innovation-heavy and pipeline-rich, but the commercial payoff is still developing and uncertain in timing and scale.

Summary

Prenetics is in transition from a one-time surge in testing revenue to a more diversified, innovation-led health and wellness platform. Financially, it remains loss-making with modest cash outflows, a small but mostly unlevered balance sheet, and limited current revenue relative to its ambitions. Strategically, it is trying to build a differentiated position through advanced genomics, early cancer detection, and a high-profile consumer wellness brand, supported by notable scientific and celebrity partnerships and an unconventional Bitcoin-based financial strategy. The key question going forward is whether these innovations can be converted into durable, scaled businesses before cash and investor patience become constraints, given the competitive and regulatory challenges in diagnostics and consumer health.